Shao-Lee Lin, Acelyrin CEO

Ace­lyrin's IL-17 in­hibitor fails to hit pri­ma­ry end­point in key study af­ter splashy IPO

Ace­lyrin said Mon­day that its lead drug izok­ibep failed to meet the pri­ma­ry end­point in a Phase IIb/III tri­al in pa­tients with hidradeni­tis sup­pu­ra­ti­va …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA